MedTrace Logo

Correlation Between Imatinib Trough Concentration and Efficacy in Advanced GIST Patients with Different Genotypes

NCT06628739 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 168

Last updated 2024-10-08

No results posted yet for this study

Summary

Imatinib (IM) has significantly enhanced the prognosis of patients (pts) with advanced gastrointestinal stromal tumors (GISTs). The clinical outcomes may correlate with IM exposure. However, the efficacy threshold, particularly based on different primary KIT mutant, remains undefined. The objective of this study is to establish the efficacy threshold of imatinib (IM) plasma trough concentration (Cmin) at steady-state in Chinese patients with advanced GIST, additionally to define subgroup thresholds based on various primary KIT mutations.

Conditions

  • Gastrointestinal Stromal Tumor, Malignant

Interventions

DRUG

Imatinib

The long-term maintenance dose of every patient was determined by the physician based on the guidelines and the patients' individual conditions such as adverse reactions.

Sponsors & Collaborators

  • First Affiliated Hospital, Sun Yat-Sen University

    lead OTHER

Principal Investigators

  • Zhang Xinhua, Professor · First Affiliated Hospital, Sun Yat-Sen University

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-07-01
Primary Completion
2022-06-30
Completion
2023-05-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06628739 on ClinicalTrials.gov